FDA and biotech news
Company news as it is published. Each story lists the tickers it names with today's move, and opens in full here.
Analyst ratings Benzinga
Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline GainsSanofi weighs potential Insmed acquisition to offset Dupixent patent loss, prompting analysts to weigh respiratory synergy against deal cost and capacity.

FDA & biotech Benzinga
Danaher Unveils Microsoft AI Partnership to Accelerate Scientific ExperimentsDanaher partners with Microsoft to build AI scientific instruments on Azure and Foundry, cutting lab experiment times by up to 83%.

FDA & biotech Benzinga
Savara Craters as FDA Delays Decision for Lung DiseaseSavara (NASDAQ: SVRA) shares fell Friday after the FDA said it will miss its November 22, 2026 PDUFA target date for molgramostim.

FDA & biotech Benzinga
Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric CancerMerck's Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary overall survival endpoint in advanced gastroesophageal cancer.

FDA & biotech Benzinga
Erasca Accelerates Pancreatic Cancer Study After Encouraging Monotherapy, Combination ResultsErasca reports strong Phase 1 tumor responses for ERAS-0015 and ERAS-4001 and accelerates its Phase 3 pancreatic cancer trial to early 2027.

FDA & biotech Benzinga
Belite Bio Stock Plunges After FDA Extends Review TimelineBelite Bio shares are sinking Friday after the FDA added three months to its review timeline of the company's application for tinlarebant.

FDA & biotech Benzinga
Bausch + Lomb Post-Surgery Eye Pain Drug Misses Study Goal But Shows Early ReliefBausch + Lomb reports Phase 2 data for eye pain drug BL1332, showing early relief and strong safety despite missing its primary endpoint.

FDA & biotech Benzinga
Celldex Drops Atopic Dermatitis Study Following Weak Phase 2 Pruritus DataCelldex halts barzolvolimab development in atopic dermatitis after Phase 2 trial misses primary itch reduction goals despite strong safety.

FDA & biotech Benzinga
Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug RegimenRevolution Medicines shares updated Phase 1/2 Rasonque data showing a 60.7% response rate and 76.6% 12-month survival in pancreatic cancer.

FDA & biotech Benzinga
Alamar Biosciences Announces New Research Published In JAMA That Uses Its NULISAqpcr eMTBR-Tau Single-Plex Assay To Evaluate Whether A Blood Test Could Identify CTE In Living PatientsNew research published in the Journal of the American Medical Association (JAMA). Researchers at Boston University CTE Center, with collaborators at Banner Health and more than 20 Institutions, used…
FDA & biotech Benzinga
Savara Says FDA Will Not Meet PDUFA Target Action Date Of November 22 For Molgramostim Inhalation Solution BLA For Treatment Of Autoimmune PAP; No Revised Action Date Communicated By The FDASavara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it…
FDA & biotech Benzinga
Belite Bio Says FDA Extends Tinlarebant NDA Review, Sets May 12, 2027 PDUFA Action DateBelite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
FDA & biotech Benzinga
Annovis Bio Receives FDA Approval Of Its Integrated Summary Of Safety Plan In Support Of Planned New Drug Application For BuntanetapU.S. Food and Drug Administration (FDA) has agreed to the Company’s Integrated Summary of Safety (ISS) plan, including a proposed strategy to pool safety data from its AD and PD clinical studies and…
Analyst ratings Benzinga
Mark Cuban Says Healthcare Economics Run On ‘Contractual Terrorism’: ‘Even the Biggest Companies Get Ripped Off’Mark Cuban says healthcare contracts are so convoluted even the biggest companies get ripped off.

Earnings Benzinga
VivoSim Labs (VIVS) Stock Jumps 21% After Hours: What’s Driving the MoveVivoSim Labs shares jumped 21.10% after hours following a seven-figure toxicology testing agreement with a global pharmaceutical company.

FDA & biotech Benzinga
DataMeds AI (MEDS) Stock Surges Over 55% After Hours: Here's WhyDataMeds AI shares surged 55.28% in after-hours after announcing an acquisition deal for cancer diagnostics assets from Todos Medical.

FDA & biotech Benzinga
With Dupixent's Patent Clock Ticking, Sanofi Circles InsmedInsmed (INSM) stock surges over 18% after reports that French pharma giant Sanofi (SNY) is exploring a potential takeover.

FDA & biotech Benzinga
NeOnc Technologies Holdings Says FDA Reschedules End-Of-Phase 1 Meeting For Oral NEO212 To November 23Meeting will address Phase 2 study design and potential regulatory pathways for oral NEO212CALABASAS, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI)…
FDA & biotech Benzinga
Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh PressureHalozyme Therapeutics shares drop after a German court overturns a preliminary injunction blocking Merck’s Keytruda SC.

